EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Resistance to Vulnerability: Therapy-Induced Surface Receptor Plasticity in ALL as an Immunotherapeutic Opportunity

Patrick A. H. Ehm, Christoph Rehbach

Hemato · 30.04.2026 · 7 (2) · 14

DOI: 10.3390/hemato7020014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, online erschienen am 30.04.2026. Verfasst von Patrick A. H. Ehm und 1 weiteren Autor:innen. Die Arbeit nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lymphoblastic leukemia (ALL) is a genetically and epigenetically heterogeneous malignant disease characterized by different subtypes with varying sensitivities to conventional chemotherapy. Despite significant improvements in survival rates, relapse remains the primary cause of treatment failure, often associated with intrinsic or acquired drug resistance. First-line therapy at diagnosis represents a major determinant of relapse in ALL. In this study, we performed a transcriptome and drug response profiling analysis to identify subtype-specific cell surface proteins that are overexpressed in patients with poor response to induction therapy. We summarize the current state of knowledge regarding chemotherapy responses, resistance mechanisms to standard cytostatic drugs and the increasing importance of cell biomarkers as predictors of an adverse disease course and potential therapeutic targets. We discuss the results of clinical and molecular studies linking specific genomic alterations—such as KMT2A-rearrangements, Ph-like, DUX4-rearrangements and T-ALL—to drug resistance and highlight surface antigens like CSPG4, HER2, MCAM and ROR1 that define high-risk leukemia phenotypes. The integration of transcriptomic, immunophenotypic and drug response data could enable a new generation of risk-adapted, surface-directed strategies for relapse treatment in ALL. Our analysis therefore provides subtype-specific predictive therapeutic targets for relapse treatment in ALL.

Zitieren

APA

Ehm, P. A. H., & Rehbach, C. (2026). From Resistance to Vulnerability: Therapy-Induced Surface Receptor Plasticity in ALL as an Immunotherapeutic Opportunity. Hemato, 7(2), 14. https://doi.org/10.3390/hemato7020014

Vancouver

Ehm PAH, Rehbach C. From Resistance to Vulnerability: Therapy-Induced Surface Receptor Plasticity in ALL as an Immunotherapeutic Opportunity. Hemato. 2026;7(2):14. doi:10.3390/hemato7020014

BibTeX
@article{Ehm2026,
  author = {Ehm, Patrick A. H. and Rehbach, Christoph},
  title = {From Resistance to Vulnerability: Therapy-Induced Surface Receptor Plasticity in ALL as an Immunotherapeutic Opportunity},
  journal = {Hemato},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {14},
  doi = {10.3390/hemato7020014}
}
Kostenlos starten →